Galapagos NV
Industriepark Mechelen Noord I, Zone L
Generaal De Wittelaan 11 A
Mechelen
B-2800
Tel: 32-15-34-29-00
Fax: 32-15-34-29-01
Website: http://www.galapagosgenomics.com/
605 articles about Galapagos NV
-
As Gilead Sciences and its development partner Galapagos NV eye filing a New Drug Application with the U.S. Food and Drug Administration for its JAK inhibitor filgotinib, the companies’ hopes have been boosted by new 52-week safety data.
-
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
8/15/2019
In early July, Gilead announced plans to submit a New Drug Application (NDA) for filgotinib for the treatment of RA in the United States before the end of the year.
-
Strong clinical progress in H1 and transformative collaboration with Gilead announced
7/25/2019
Galapagos NV announces its unaudited first half-year results, which are further detailed in its H1 2019 report available on the Galapagos website, www.glpg.com.
-
Galapagos will receive $3.95 billion in upfront cash, as well as a $1.1 billion equity investment from Gilead as the California company gains access to numerous compounds in Galapagos' pipeline.
-
Gilead and Galapagos Enter Into Transformative Research and Development Collaboration
7/14/2019
Gilead Sciences, Inc. and Galapagos NV announced that they have entered into a 10-year global research and development collaboration.
-
Galapagos increases share capital through warrant exercises on 20 June 2019
6/20/2019
Galapagos NV announces a share capital increase arising from warrant exercises.
-
Galapagos NV received a transparency notification from The Capital Group Companies, Inc.
6/17/2019
Galapagos NV received a transparency notification from The Capital Group Companies, Inc.
-
Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
6/11/2019
Servier and Galapagos NV completed recruitment for their ROCCELLA Phase 2 trial with GLPG1972/S201086, ahead of schedule.
-
Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019)
5/29/2019
Phase 3 FINCH 1 and FINCH 3 Data of Filgotinib in Rheumatoid Arthritis to Be Featured in Opening Plenary and Late Breaker Sessions
-
Galapagos reports on historic first quarter 2019
4/25/2019
Galapagos NV presents financial results and highlights the key events for the first quarter of 2019.
-
MorphoSys and Galapagos Announce Initiation of GECKO Phase 2 Study with MOR106 in Atopic Dermatitis Patients
4/23/2019
MorphoSys AG, Galapagos NV and Novartis Pharma AG announced the initiation of GECKO, a phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
-
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
4/23/2019
Galapagos NV, MorphoSys AG and Novartis Pharma AG announced the initiation of GECKO, a Phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
-
Galapagos creates new warrant plans
4/10/2019
Galapagos NV announced that its board of directors created 2,070,000 warrants under new warrant plans for the benefit of the employees, directors, and a consultant of the company and its subsidiaries.
-
Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2018
3/29/2019
Galapagos NV published its annual report for the financial year 2018.
-
Gilead Sciences and Belgium-based Galapagos NV reported positive late-stage results from its FINCH 1 and FINCH 3 rheumatoid arthritis studies.
-
Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients
3/28/2019
Filgotinib 100 mg and 200 mg Plus Methotrexate (MTX) Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone
-
Galapagos increases share capital through warrant exercises on 20 March 2019
3/20/2019
Galapagos NV announces a share capital increase arising from warrant exercises.
-
Positive Readouts for Axsome and Galapagos Could Cause Stocks to Skyrocket, Analyst Predicts
3/8/2019
In February, Galapagos NV Chief Executive Officer Onno van de Stolpe promised that 2019 will be a “data rich year” for the Belgium-based company and its lead product, filgotinib. -
Firmly on our way to becoming a fully integrated biopharma company
2/21/2019
FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability
-
Evotec and Galapagos enter into collaboration in the field of fibrosis
2/7/2019
Mechelen, Belgium, and Hamburg, Germany; 7 February 2019, 7.30 CET - Evotec AG, and Galapagos NV announced a global collaboration focused on a novel target for fibrosis and other indications.